Current Controlled Substance Monitoring Programs Are Causing Patients Harm
July 1st 2023We all have an interest in reducing harm and deaths from opiates and other controlled substances, but we should have evidence-based and patient-centered approaches that do not have unintended consequences on patient health and safety.
Read More
Patient-Reported Questionnaire Could Aid the Evaluation of Respiratory Syncytial Virus Symptoms
June 30th 2023Findings suggest that psychometric tests used for The Respiratory Infection Intensity and Impact Questionnaire provide reliable, construct validity, and responsive evidence to detect onset symptoms of RSV.
Read More
Busting Common Medication Myths: Pharmacists Empowering Patients with Accurate Information
June 30th 2023As one of the most trusted health care professionals, pharmacists play a vital role in debunking medication myths by providing patients with accurate information to make positive decisions regarding their health.
Read More
Galcanezumab-gnlm Demonstrates Clinically Meaningful Efficacy, Safety in 3 Months for Migraine
June 30th 2023Galcanezumab-gnlm (Emgality; Eli Lilly and Company) did not demonstrate superiority to rimegepant orally disintegrating tablet (Nurtec ODT) on the percentage of individuals achieving a 50% or greater reduction in monthly migraine headache days.
Read More
What is 340B? Exploring Pharmacist Contributions, its Important Role in Hospitals
June 29th 2023The impact of pharmacist on reducing medication expenses cannot be overstated as they leverage their medication management expertise within hospital settings through collaboration with the 340B program.
Read More
Study: Genentech’s Herceptin Lost Market Share After Introduction of First Trastuzumab Biosimilar
June 29th 2023Investigators found that the first biosimilar of trastuzumab, trastuzumab-anns (Kanjinti; Amgen), did maintain a strong and persistent advantage over the other 4 biosimilar entrants.
Read More